Nature Communications (May 2020)
Multi-omic single-cell snapshots reveal multiple independent trajectories to drug tolerance in a melanoma cell line
- Yapeng Su,
- Melissa E. Ko,
- Hanjun Cheng,
- Ronghui Zhu,
- Min Xue,
- Jessica Wang,
- Jihoon W. Lee,
- Luke Frankiw,
- Alexander Xu,
- Stephanie Wong,
- Lidia Robert,
- Kaitlyn Takata,
- Dan Yuan,
- Yue Lu,
- Sui Huang,
- Antoni Ribas,
- Raphael Levine,
- Garry P. Nolan,
- Wei Wei,
- Sylvia K. Plevritis,
- Guideng Li,
- David Baltimore,
- James R. Heath
Affiliations
- Yapeng Su
- Division of Chemistry and Chemical Engineering, California Institute of Technology
- Melissa E. Ko
- Cancer Biology Program, Stanford University School of Medicine
- Hanjun Cheng
- Institute for Systems Biology
- Ronghui Zhu
- Division of Biology and Biological Engineering, California Institute of Technology
- Min Xue
- Division of Chemistry and Chemical Engineering, California Institute of Technology
- Jessica Wang
- Division of Biology and Biological Engineering, California Institute of Technology
- Jihoon W. Lee
- Division of Chemistry and Chemical Engineering, California Institute of Technology
- Luke Frankiw
- Division of Biology and Biological Engineering, California Institute of Technology
- Alexander Xu
- Institute for Systems Biology
- Stephanie Wong
- Division of Biology and Biological Engineering, California Institute of Technology
- Lidia Robert
- Department of Medicine, University of California, Los Angeles
- Kaitlyn Takata
- Division of Biology and Biological Engineering, California Institute of Technology
- Dan Yuan
- Institute for Systems Biology
- Yue Lu
- Institute for Systems Biology
- Sui Huang
- Institute for Systems Biology
- Antoni Ribas
- Department of Medicine, University of California, Los Angeles
- Raphael Levine
- Department of Molecular and Medical Pharmacology, UCLA
- Garry P. Nolan
- Department of Microbiology and Immunology, Stanford University
- Wei Wei
- Institute for Systems Biology
- Sylvia K. Plevritis
- Department of Radiology, Stanford University
- Guideng Li
- Center of Systems Medicine, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College
- David Baltimore
- Division of Biology and Biological Engineering, California Institute of Technology
- James R. Heath
- Division of Chemistry and Chemical Engineering, California Institute of Technology
- DOI
- https://doi.org/10.1038/s41467-020-15956-9
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 12
Abstract
Detailed understanding of how cancer cells transition from a drug sensitive to a tolerant state is lacking. Here, using single cell proteomic and metabolic data the authors uncover that isogenic BRAF mutant melanoma cells can take two distinct paths to become tolerant to BRAF inhibition.
